[6-K] EUPRAXIA PHARMACEUTICALS INC. Current Report (Foreign Issuer)
EUPRAXIA PHARMACEUTICALS INC. submitted a Form 6-K reporting its principal executive office address in Victoria, British Columbia, and indicated it files annual reports under Form 40-F. The report includes an exhibit: Exhibit 99.1, a press release dated September 22, 2025. The document is signed by Alex Rothwell, Chief Financial Officer, dated September 22, 2025. The filing appears to be a routine disclosure providing company contact details, the chosen annual-reporting form and a referenced press release.
EUPRAXIA PHARMACEUTICALS INC. ha inviato un Form 6-K che riporta l'indirizzo della sua sede principale a Victoria, British Columbia, e indica che presenta report annuali tramite Form 40-F. Nel rapporto è presente una dichiarazione allegata: Exhibit 99.1, un comunicato stampa datato 22 settembre 2025. Il documento è firmato da Alex Rothwell, Chief Financial Officer, datato 22 settembre 2025. L'invio sembra una disclosure di routine che fornisce i contatti dell'azienda, il modulo annuale scelto per la rendicontazione e un comunicato stampa di riferimento.
EUPRAXIA PHARMACEUTICALS INC. presentó un Form 6-K que indica la dirección de su oficina principal en Victoria, Columbia Británica, y señala que presenta informes anuales bajo Form 40-F. El informe incluye un anexo: Exhibit 99.1, un comunicado de prensa con fecha 22 de septiembre de 2025. El informe está firmado por Alex Rothwell, Director Financiero (CFO), con fecha 22 de septiembre de 2025. La presentación parece una divulgación de rutina que ofrece los datos de contacto de la empresa, el formulario anual elegido y un comunicado de prensa referenciado.
EUPRAXIA PHARMACEUTICALS INC.은 Victoria, British Columbia에 있는 주요 경영 본사 주소를 보고하고 연례 보고서는 Form 40-F를 통해 제출한다고 Form 6-K를 제출했습니다. 보고서에는 Exhibit 99.1, 2025년 9월 22일자로 된 보도자료가 포함된 부속품이 있습니다. 문서는 Alex Rothwell 최고재무책임자(CFO)가 서명했고 날짜는 2025년 9월 22일입니다. 이 제출은 회사의 연락처 정보, 선택된 연례 보고 양식 및 참조된 보도자료를 제공하는 일상적인 공시로 보입니다.
EUPRAXIA PHARMACEUTICALS INC. a soumis un Form 6-K indiquant l'adresse de son siège social principal à Victoria, Colombie-Britannique, et a précisé qu’elle dépose des rapports annuels sous le Form 40-F. Le rapport comprend une pièce jointe : Exhibit 99.1, un communiqué de presse daté du 22 septembre 2025. Le document est signé par Alex Rothwell, Chief Financial Officer, daté du 22 septembre 2025. Cette dépôt semble être une communication de routine fournissant les coordonnées de l’entreprise, le formulaire annuel choisi et le communiqué de presse référencé.
EUPRAXIA PHARMACEUTICALS INC. hat ein Form 6-K eingereicht, in dem die Hauptgeschäftsadresse in Victoria, British Columbia, angegeben wird, und darauf hingewiesen, dass jährliche Berichte unter dem Form 40-F eingereicht werden. Der Bericht enthält eine Anhörung: Exhibit 99.1, eine Pressemitteilung datiert auf den 22. September 2025. Das Dokument ist von Alex Rothwell, Chief Financial Officer, datiert auf den 22. September 2025, unterschrieben. Die Einreichung scheint eine routinemäßige Offenlegung zu sein, die Kontaktdaten des Unternehmens, das gewählte Jahresberichtsformular und eine referenzierte Pressemitteilung enthält.
قدمت EUPRAXIA PHARMACEUTICALS INC. نموذج 6-K يذكر عنوان مكتبها التنفيذي الرئيسي في فيكتوريا، كولومبيا البريطانية، وتذكر أنها تقارير سنوية بموجب Form 40-F. يتضمن التقرير ملحقاً: Exhibit 99.1، بيان صحفي مؤرخ في 22 سبتمبر 2025. المستند موقع من Alex Rothwell، المدير المالي التنفيذي، والمؤرخ في 22 سبتمبر 2025. يبدو أن الإيداع إعلانات روتينية توفر تفاصيل اتصال الشركة، النموذج السنوي المختار للتقارير وبيان الصحافة المشار إليه.
EUPRAXIA PHARMACEUTICALS INC. 已提交 Form 6-K，披露其主要办公地址位于不列颠哥伦比亚省维多利亚市，并指出其按 Form 40-F 提交年度报告。该报告包含一个附件：Exhibit 99.1，日期为 2025 年 9 月 22 日 的新闻稿。该文件由 Alex Rothwell，首席财务官签署，日期为 2025 年 9 月 22 日。该提交看似一项常规披露，提供公司的联系信息、所选年度报告表格以及所述新闻稿。
- None.
- None.
Insights
TL;DR: Routine Form 6-K disclosing Form 40-F filing status, contact details and an attached press release; procedural compliance, not material news.
This filing confirms the registrant's chosen annual-reporting vehicle (Form 40-F) and supplies corporate contact information. The inclusion of Exhibit 99.1 (a press release dated September 22, 2025) indicates supplementary disclosure was furnished to the market. There are no financial statements, transaction details, or operational metrics in the provided text. From a compliance perspective, the report satisfies routine disclosure obligations but does not present new material facts requiring investor revaluation.
TL;DR: Administrative filing that documents corporate address, reporting form and an attached press release; governance implications are minimal.
The document is signed by the CFO, demonstrating appropriate authorized execution. Designation of Form 40-F confirms the company follows the disclosure regime applicable to certain foreign issuers. No governance changes, executive appointments, or material transactions are reported in the provided content. This appears to be a standard disclosure packet rather than a governance event.
EUPRAXIA PHARMACEUTICALS INC. ha inviato un Form 6-K che riporta l'indirizzo della sua sede principale a Victoria, British Columbia, e indica che presenta report annuali tramite Form 40-F. Nel rapporto è presente una dichiarazione allegata: Exhibit 99.1, un comunicato stampa datato 22 settembre 2025. Il documento è firmato da Alex Rothwell, Chief Financial Officer, datato 22 settembre 2025. L'invio sembra una disclosure di routine che fornisce i contatti dell'azienda, il modulo annuale scelto per la rendicontazione e un comunicato stampa di riferimento.
EUPRAXIA PHARMACEUTICALS INC. presentó un Form 6-K que indica la dirección de su oficina principal en Victoria, Columbia Británica, y señala que presenta informes anuales bajo Form 40-F. El informe incluye un anexo: Exhibit 99.1, un comunicado de prensa con fecha 22 de septiembre de 2025. El informe está firmado por Alex Rothwell, Director Financiero (CFO), con fecha 22 de septiembre de 2025. La presentación parece una divulgación de rutina que ofrece los datos de contacto de la empresa, el formulario anual elegido y un comunicado de prensa referenciado.
EUPRAXIA PHARMACEUTICALS INC.은 Victoria, British Columbia에 있는 주요 경영 본사 주소를 보고하고 연례 보고서는 Form 40-F를 통해 제출한다고 Form 6-K를 제출했습니다. 보고서에는 Exhibit 99.1, 2025년 9월 22일자로 된 보도자료가 포함된 부속품이 있습니다. 문서는 Alex Rothwell 최고재무책임자(CFO)가 서명했고 날짜는 2025년 9월 22일입니다. 이 제출은 회사의 연락처 정보, 선택된 연례 보고 양식 및 참조된 보도자료를 제공하는 일상적인 공시로 보입니다.
EUPRAXIA PHARMACEUTICALS INC. a soumis un Form 6-K indiquant l'adresse de son siège social principal à Victoria, Colombie-Britannique, et a précisé qu’elle dépose des rapports annuels sous le Form 40-F. Le rapport comprend une pièce jointe : Exhibit 99.1, un communiqué de presse daté du 22 septembre 2025. Le document est signé par Alex Rothwell, Chief Financial Officer, daté du 22 septembre 2025. Cette dépôt semble être une communication de routine fournissant les coordonnées de l’entreprise, le formulaire annuel choisi et le communiqué de presse référencé.
EUPRAXIA PHARMACEUTICALS INC. hat ein Form 6-K eingereicht, in dem die Hauptgeschäftsadresse in Victoria, British Columbia, angegeben wird, und darauf hingewiesen, dass jährliche Berichte unter dem Form 40-F eingereicht werden. Der Bericht enthält eine Anhörung: Exhibit 99.1, eine Pressemitteilung datiert auf den 22. September 2025. Das Dokument ist von Alex Rothwell, Chief Financial Officer, datiert auf den 22. September 2025, unterschrieben. Die Einreichung scheint eine routinemäßige Offenlegung zu sein, die Kontaktdaten des Unternehmens, das gewählte Jahresberichtsformular und eine referenzierte Pressemitteilung enthält.
FAQ
What reporting form does EPRX indicate it files for annual reports?
What exhibit is included with the 6-K for EPRX?
What is the principal executive office address listed for EPRX?
Who signed the Form 6-K for EUPRAXIA PHARMACEUTICALS INC.?
Does this Form 6-K include financial statements or transaction details?
